Wegovy semaglutide tablets and the Wegovy injection contain the same active ingredient and produce broadly comparable weight loss results, but they work differently in practice. One is a once-weekly subcutaneous injection; the other is a daily tablet with specific fasting requirements. Both are clinically significant options, though in the UK only the injection is currently available - the tablet is under MHRA review with a decision expected in late 2026.
This guide covers how the two forms compare on mechanism, clinical trial results, side effects, dosing routine, and practical fit, so you can make an informed decision about which may suit you.
Same Active Ingredient, Different Delivery
Both Wegovy tablets and the Wegovy injection contain semaglutide, a GLP-1 receptor agonist that works by mimicking a hormone your gut releases naturally after eating. Semaglutide acts on receptors in the brain and gut to reduce appetite, slow gastric emptying, and decrease the reward response to food. The result is that most people eat less without the persistent hunger that makes dieting difficult.
The core pharmacology is identical. What differs is how semaglutide enters your bloodstream, how frequently you take it, and the practical demands each route places on your routine.
How Do the Two Forms Differ?
Wegovy Injection
The injection delivers semaglutide subcutaneously, meaning directly under the skin of the abdomen, thigh, or upper arm using a pre-filled pen device. It's taken once weekly and absorption is reliable and consistent, with less day-to-day variability in blood levels. No fasting is required before or after the injection, and there are no food or drink restrictions around the dose.
The dose escalation schedule for the injection runs over 16 to 20 weeks, starting at 0.25mg weekly and increasing to a maintenance dose of 2.4mg weekly. A higher dose of 7.2mg weekly was approved by the MHRA in early 2026 for those who need it.
Wegovy Tablets
Delivering semaglutide orally is technically more complex than injection, because the protein would normally be broken down in the stomach before it could be absorbed. To overcome this, the tablet is co-formulated with a compound called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which temporarily increases the permeability of the stomach lining and allows semaglutide to pass into the bloodstream before it reaches the small intestine.1
Even with SNAC technology, only a very small fraction of each oral dose reaches the bloodstream, which is why the tablet dose is substantially higher than the injection: 25mg daily compared to 2.4mg weekly by injection. The tablet must be taken once daily on an empty stomach with no more than 120ml of plain water, and you must wait at least 30 minutes before eating, drinking anything other than water, or taking other medications.2 Food in the stomach significantly reduces semaglutide absorption through this route.
This 30-minute morning window is the single most important practical difference between the two forms. For some people, it fits naturally into a morning routine. For others, it presents a daily constraint that the injection does not.
What Do the Clinical Trials Show?
The two forms of Wegovy have been studied in separate clinical trial programmes: the STEP trials for the injection, and the OASIS trials for the tablet.
Injection: STEP 1 Trial
The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity or overweight alongside at least one weight-related health condition. Participants taking semaglutide 2.4mg by injection once weekly for 68 weeks lost an average of 14.9% of their starting body weight, compared to 2.4% with placebo. Around 86% of those on semaglutide lost at least 5% of their body weight, and over half lost 15% or more.3
Tablet: OASIS 4 Trial
The OASIS 4 trial, published in the New England Journal of Medicine in September 2025, studied oral semaglutide 25mg once daily in 307 adults with obesity or overweight. Over 64 weeks, participants lost an average of 13.6% of their starting body weight, compared to 2.2% with placebo. Among those who remained fully adherent to treatment, average weight loss reached 16.6%. Around 30% of participants on the tablet lost 20% or more of their body weight.4
Pooled analyses from the OASIS programme presented at ObesityWeek 2025 confirmed that oral and injectable semaglutide produced comparable weight loss and cardiometabolic outcomes across multiple secondary endpoints, including reductions in blood pressure, fasting glucose, and cholesterol.
Comparing the Two
The injection produces slightly more consistent weight loss across the population as a whole, which likely reflects both the modestly longer trial duration (68 weeks versus 64 weeks for OASIS 4) and the greater day-to-day variability in oral semaglutide absorption. The practical gap, however, is small: both forms produce clinically significant weight loss of around 13 to 17%, and both far outperform placebo. For most people, the difference in average outcomes is unlikely to be the deciding factor. What matters more is which form you can use consistently over the long term.
Side Effects: Are They the Same?
Because both forms contain semaglutide, the side effect profile is broadly similar. The most commonly reported effects across both the STEP and OASIS trials are nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. Most gastrointestinal symptoms are mild to moderate, tend to occur during dose escalation, and settle as the body adjusts.4
There are two meaningful differences between the forms:
- Injection-site reactions (redness, bruising, or irritation at the injection site) only occur with the pen. They are uncommon but are specific to the injectable route.
- Vomiting was reported slightly more frequently with the tablet at its full dose in clinical trials, and absorption variability may mean some people experience more pronounced nausea on certain days.
Both forms carry the same contraindications. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Anyone with a history of pancreatitis should discuss treatment suitability with a prescriber before starting.
UK Availability in 2026
The Wegovy injection is currently available by private prescription in the UK. The standard 2.4mg dose has been available since 2023, and the MHRA approved a 7.2mg single-dose pen in April 2026 for patients requiring the higher maintenance dose.5
The Wegovy tablet has not been approved by the MHRA as of June 2026. It's currently under regulatory review, with a decision expected later in 2026. If approved, private prescription availability would be expected to follow shortly after, though NHS access via NICE is unlikely before 2027 at the earliest. Only the tablet's licensed UK indication, dosing schedule, and eligibility criteria will be confirmed at the point of MHRA approval.
Currently, the only oral semaglutide licensed in the UK is Rybelsus, which contains a lower dose of semaglutide and is approved for type 2 diabetes only, not for weight management.
Which Option Is Right for You?
The injection and the tablet are not competing treatments so much as two routes to the same outcome. The right choice depends on practical fit rather than clinical superiority.
The injection may be a better fit if you prefer a once-weekly routine without any daily food restrictions, or if you want to start treatment now using an already-licensed UK option.
The tablet may be worth considering if you have a strong aversion to needles or prefer a daily oral routine, and you're willing to plan around the morning fasting requirement. If MHRA approval is granted, it will offer an alternative for people who have avoided injectable treatment.
It's also worth noting that consistency of use is likely a stronger predictor of outcome than which form you choose. A treatment you take reliably every day or week will outperform one you find difficult to maintain, regardless of the trial averages.
If you're unsure which option suits your lifestyle, speak to a prescriber who can take your full medical history and preferences into account.
When to Seek Further Advice
Contact your GP or prescribing clinician if you:
- Experience severe or persistent nausea, vomiting, or upper abdominal pain that does not resolve
- Develop symptoms consistent with pancreatitis: severe upper abdominal pain that radiates to the back, particularly after eating
- Notice any lump or swelling in the neck, or have difficulty swallowing or breathing
- Are taking other medications and want to confirm whether timing adjustments are needed
A full list of known side effects and drug interactions is available in the patient information leaflet supplied with your medication. If you have any concerns about your treatment, speak to your prescribing pharmacist or GP.
Frequently Asked Questions
Is the Wegovy tablet available in the UK?
Not yet. As of June 2026, Wegovy semaglutide tablets have not been approved by the MHRA. The tablet is currently under regulatory review, with a decision expected in late 2026. If approved, it is likely to become available by private prescription shortly after. The Wegovy injection is available in the UK now.
Do Wegovy semaglutide tablets produce the same weight loss as the injection?
The results are comparable. In the OASIS 4 trial, people taking Wegovy semaglutide tablets 25mg once daily lost an average of 13.6% of their body weight over 64 weeks, with full-adherence participants averaging 16.6%. The STEP 1 trial for the injection produced 14.9% average weight loss over 68 weeks. Both forms far outperform placebo, and the practical gap between them is small.
Why is the dose of the tablet so much higher than the injection?
Because far less of an oral dose reaches the bloodstream. Semaglutide taken by mouth is largely broken down in the stomach before it can be absorbed. The tablet uses a compound called SNAC to help semaglutide pass through the stomach lining, but even so, only a small fraction of each dose gets through. A 25mg daily tablet is needed to achieve blood levels roughly equivalent to those produced by a 2.4mg weekly injection.
Do you have to fast before taking Wegovy semaglutide tablets?
Yes. The tablet must be taken on an empty stomach with no more than 120ml of plain water, and you must wait at least 30 minutes before eating, drinking anything other than water, or taking other medications. Food significantly reduces absorption. This is the most important daily requirement of the tablet that the injection does not share.
Are the side effects of the tablet and injection the same?
Broadly yes. Both forms most commonly cause nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation. Two differences stand out: injection-site reactions only occur with the pen, and vomiting was reported slightly more often with the tablet at full dose in clinical trials. The overall safety profile of both forms is consistent with the GLP-1 class of medicines.
Can you switch from the Wegovy injection to the tablet?
Switching will become a practical option once Wegovy semaglutide tablets are approved in the UK. Once available, a prescriber would be able to advise on the appropriate starting dose for the tablet and how to manage the transition. It is not advisable to switch independently or to use unlicensed oral semaglutide products in the meantime.
Is Rybelsus the same as the Wegovy tablet?
Both contain semaglutide as the active ingredient, but they are different products. Rybelsus is a lower-dose oral semaglutide tablet (up to 14mg) licensed in the UK for type 2 diabetes, not for weight loss. Wegovy semaglutide tablets contain a higher dose (25mg) formulated specifically for weight management. Rybelsus is not a substitute for Wegovy semaglutide tablets and should not be used off-label for weight loss.
References
- Buckley ST, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
- US Food and Drug Administration. Wegovy (semaglutide) oral tablet 25mg: Prescribing Information. FDA; 2025. Accessed June 2026
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
- Medicines and Healthcare products Regulatory Agency. Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity. GOV.UK; April 2026. gov.uk/mhra
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns about your treatment.